Objective:To observe the clinical efficacy of Feiyiliu mixture and AP chemotherapy (pemetrexed + cis-platinum) in the treatment of non-small cell lung cancer and its effect on inflammatory factors. Method:The 62 patients with non-small cell lung cancer who met the inclusion criteria were randomly divided into the control group and the treatment group

with 31 patients in each group. The control group was given AP chemotherapy regimen and compound cantharis capsule

3 pills/time

bid; the treatment group was orally given Feiyiliu mixture in addition of AP regimen

100 mL/time

tid. The changes in scores of quality of life

symptom scores

interleukin (IL)-6

IL-17

prostaglandin E2 (PGE2) solid tumor after treatment

and incidence of adverse events were observed in two groups before and after treatment

and the clinical efficacy was evaluated. Result:The treatment group's scores of quality of life

integral syndrome (cough

hemoptysis

chest pain

fatigue and fever) and cytokines (IL-6

IL-17

PGE2) after treatment were significantly lower than those of control group (P<0.05); the rate of tumor stability after treatment was significantly better than that of control group (P<0.05); the incidence of adverse events was lower than that of control group (P < 0.05). Conclusion:Feiyiliu mixture combined with AP chemotherapy can effectively improve quality of life

clinical symptoms and tumor size in patients with non-small cell lung cancer

and decrease the expressions of inflammatory cytokines in serum of the patients

and is worth further promotion.